Kymera Therapeutics Inc (KYMR NASDAQ) stock market data APIs
$75.1434
-3.11(-4.1%)
as of February 2, 2026
Try our APIs with
free plan!
Kymera Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
75.1434
Open
72.0316
High
75.1593
Low
71.8567
52 wk Range
19.445-103
Market Cap
6 050 M
Shares Outstanding
79 999 K
Revenue
43 735 K
EPS
-0.94
Beta
2.256
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kymera Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kymera Therapeutics Inc data using free add-ons & libraries
Get Kymera Therapeutics Inc Fundamental Data
Kymera Therapeutics Inc Fundamental data includes:
- Net Revenue: 43 735 K
- EBITDA: -321 535 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -0.8613
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kymera Therapeutics Inc News
New
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Kymera Therapeutics started dosing patients in its BREADTH Phase 2b trial of KT-621, an ora...
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to-severe eosinophilic asthma. KT-621 is an investigational, first-in-class, ...
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics, Inc. Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to ...
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick o...
Get Kymera Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
